Macrobrachium rosenbergii nodavirus (MrNV) is a virus native to giant freshwater prawn. Recombinant MrNV capsid protein has been produced in Escherichia coli, which selfassembled into virus-like particles (VLPs). However, this recombinant protein is unstable, degrading and forming heterogenous VLPs. In this study, MrNV capsid protein was produced in insect Spodoptera frugiperda (Sf9) cells through a baculovirus system. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) revealed that the recombinant protein produced by the insect cells self-assembled into highly stable, homogenous VLPs each of approximately 40 nm in diameter. Enzyme-linked immunosorbent assay (ELISA) showed that the VLPs produced in Sf9 cells were highly antigenic and comparable to those produced in E. coli. In addition, the Sf9 produced VLPs were highly stable across a wide pH range (2-12). Interestingly, the Sf9 produced VLPs contained DNA of approximately 48 kilo base pairs and RNA molecules. This study is the first report on the production and characterization of MrNV VLPs produced in a eukaryotic system. The MrNV VLPs produced in Sf9 cells were about 10 nm bigger and had a uniform morphology compared with the VLPs produced in E. coli. The insect cell production system provides a good source of MrNV VLPs for structural and immunological studies as well as for host-pathogen interaction studies.
Introduction
Macrobrachium rosenbergii nodavirus (MrNV) is the causative agent for White Tail Disease (WTD), an infectious killer disease in post larvae of M. rosenbergii, the giant freshwater prawn. The disease was first reported in 1994 in Guadelope, French West Indies and then spread rapidly to countries around the Pacific and Indian Oceans including China, India, Taiwan, Thailand, Malaysia, and Australia. [1] [2] [3] [4] [5] [6] [7] The mortality rates in larvae and post-larvae of M. rosenbergii can reach up to 100%. This caused great economic losses to the M. rosenbergii hatchery and nursery farm industries. thus making the infected adult prawns virus carriers, transmitting the virus both vertically to their offspring, and horizontally to other prawns during cannibalization. 3, 9 MrNV belongs to the family Nodaviridae which generally contains two genera: the Alpha-nodavirus that infects insects, and the Beta-nodavirus that infects fishes. MrNV has been proposed to be grouped into a new genus, the Gamma-nodavirus which infects prawns. 10 Prawn nodavirus includes MrNV and Penaeus vannamei nodavirus (PvNV). Despite infecting a different host, MrNV in general is still similar to the other family members with a bipartite single stranded RNA genome which is encapsidated by monomeric capsid proteins. The bipartite RNA molecules, namely RNA1 and RNA2 are 3.2 kilo bases (kb) and 1.2 kb in length, respectively. RNA1 encodes the RNA-dependent RNA polymerase (RdRp) and RNA2 encodes the viral capsid protein. 11 Recently, the MrNV capsid protein produced in prokaryotic cells had been studied extensively. Goh et al. 12, 13 studied the molecular biology of the virus-like particles (VLPs), Jariyapong et al. 14, 15 employed the VLPs as a carrier for DNA and RNA, Yong et al. 16, 17 applied the VLPs as a platform for foreign epitope display, whereas Farook et al. 18 used the VLPs as a vaccine against WTD. However, the N-terminal end of the MrNV capsid protein produced in Escherichia coli is partially degraded, which could be the main reason that the MrNV VLPs produced in the prokaryotic host are less uniform in shape. 12 Therefore, in this study, MrNV capsid protein was produced in Spodoptera frugiperda (Sf9) cells using the Bac-to-Bac V R Baculovirus Expression System (Invitrogen). This system utilizes the site-specific transposition of Tn7 transposon as a means to transfer the expression cassette in a recombinant plasmid vector (pFastBac TM ) carrying the gene of interest into the baculovirus shuttle vector (bacmid) in E. coli DH10Bac TM . The recombinant bacmid was then introduced into Sf9 cells for high-level protein expression under the regulation of the Autographa california multiple nuclear polyhedrosis virus (AcMNPV) polyhedrin promoter. Sf9 cell was chosen due to its close similarities with the native host of MrNV, since both insects and prawns belong to the phylum Arthropoda.
The MrNV capsid protein produced in Sf9 cells selfassembled into VLPs of high homogeneity, which serves as an excellent candidate to be used in structural studies, such as crystallization, cryo-electron microscopy, or nuclear magnetic resonance imaging. To the best of our knowledge, the production and characterization of MrNV VLPs in a eukaryotic expression system has not yet been reported. Thus, the recombinant MrNV VLPs produced in Sf9 cells were then characterized and compared with those produced in E. coli.
Materials and Methods

Construction of recombinant bacmid harboring the gene of MrNV capsid protein
The gene encoding MrNV capsid protein in plasmid pTrcHis2-TARNA2 12 was subcloned into pFastBac HT-C vector (Invitrogen). Primers Nco-Forward [5 0 -CCC GCC CAT GGC TAG AGG TAA AC-3 0 (the NcoI restriction site is underlined)] and Eco-Reverse [5 0 -CCG AAT TCA ATT ATT GCC GAC GAT AGC-3 0 (the EcoRI restriction site is underlined)] were used to amplify the gene encoding MrNV capsid protein from the plasmid by polymerase chain reaction (PCR). The initial DNA denaturation was carried out at 958C for 5 min, followed by 32 cycles of DNA amplification (denaturation at 948C for 45 s; annealing at 56.88C for 1 min; extension at 728C for 2 min) and a final extension at 728C for 30 min. The PCR products were excised and purified using the Qiaquick Gel Extraction Kit (Qiagen, Germany). The purified DNA was digested with NcoI and EcoRI and ligated with the linearized pFastBac HT-C vector via the same restriction sites.
The ligation mixture was introduced into the MAX Efficiency DH10Bac competent cells (Invitrogen) via heat shock at 428C for 1 min. The transformed cells were plated onto Luria Broth (LB) agar containing kanamycin (50 mg/mL), tetracycline (10 mg/mL), and gentamicin (7 mg/mL). White colonies formed on the plate were screened by PCR using pUC/M13 forward (5 0 -CCC AGT CAC GAC GTT GTA AAA CG-3 0 ) and reverse (5 0 -AGC GGA TAA CAA TTT CAC ACA GG-3 0 ) primers. The PCR conditions were 948C for 4 min, followed by 30 cycles of amplification (denaturation at 948C for 45 s; annealing at 568C for 1 min; extension at 728C for 4 min) and a final extension at 728C for 7 min. The positive transformants were grown in LB broth (5 mL) overnight at 378C with shaking (220 rpm). Bacmid DNA was then extracted using the alkaline lysis method. 19 Cell culture and generation of recombinant baculovirus Sf9 cells were cultured at 278C in Sf-900 III SFM (Life Technologies) supplemented with 4% fetal bovine serum (FBS). The procedure for the generation of recombinant baculovirus was modified from that of Dezfooli et al. 20 For transfection of Sf9 cells with bacmid, 8 3 10 5 cells were seeded into each well of the 6-well plate with the Grace's Insect Medium (Life Technologies) and incubated for 1 h. Bacmid DNA (50-200 ng) and Cellfectin II (8 mL; Life Technologies) were added separately into two different tubes containing the Grace's Insect Medium (100 mL). They were then mixed together and incubated for 20 min at room temperature. The DNA-lipid mixture was added dropwise onto the Sf9 cells and incubated for 5 h at 278C. The transfection mixture was then removed and replaced with Sf-900 III SFM supplemented with 4% FBS. At 4-day post transfection, the culture medium was harvested and stored at 48C as passage one (P1) viral stock. The proteins in the culture supernatant and cell lysate were precipitated separately at 50% ammonium sulphate saturation. The proteins were resuspended in sodium phosphate buffer (77.4 mM Na 2 HPO 4 , 22.6 mM NaH 2 PO 4 ; pH 7.4), layered on top of a sucrose gradient [10-40% (w/v)] and centrifuged at 150,000g for 4.5 h at 48C using the SW 40 Ti rotor (Beckman Coulter). The samples were fractionated (1 mL each) and analyzed using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Fractions containing the recombinant protein were pooled and dialyzed in sodium phosphate buffer.
Protein expression and purification
SDS-PAGE and Western blotting
MrNV capsid proteins expressed in E. coli were produced and purified according to the previously described method. 12 Protein samples from both E. coli and Sf9 cells were mixed with 63 sample buffer [350 mM Tris-HCl; pH 6.8, 30% (v/v) glycerol, 10% (w/v) sodium dodecyl phosphate (SDS), 0.1% (w/v) bromophenol blue, 6% (v/v) 2-mercaptoethanol] separately and boiled for 10 min before being loaded onto 12% SDS-polyacrylamide gel. The gel was electrophoresed and stained with Coomassie Brilliant Blue R-250. For Western blotting, the proteins on the gel were electroblotted onto a nitrocellulose membrane. The membrane was then blocked with skimmed milk [10% (w/v) in TBS (50 mM Tris-HCl, 150 mM NaCl; pH 7.4)] for 1 h at 48C and washed three times with TBST [0.01% (v/v) Tween-20 in TBS]. The membrane was added with a mouse anti-His monoclonal antibody (1:5000 dilution in TBS; Invitrogen) or a rabbit anti-MrNV capsid protein serum raised with the recombinant MrNV capsid protein purified from E. coli. 12 The rabbit serum was diluted 25003 with TBS, and adsorbed with E. coli host proteins. The membrane was then incubated with the primary antibody for 1 h at 48C, and rinsed three times with TBST. Alkaline phosphatase-conjugated anti-mouse antibody (1:5000 dilution in TBS; KPL) or anti-rabbit antibody (1:5000 dilution in TBS; KPL) was added to the membrane and incubated for 1 h at room temperature. The membrane was then washed three times (5 min incubation each) with TBST and the color was developed by adding alkaline phosphatase buffer (100 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl 2 ; pH 9.5) containing 3.5 mM 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and 3.7 mM nitro blue tetrazolium (NBT).
Transmission electron microscopy of MrNV VLPs
MrNV VLPs purified from E. coli as well as from Sf9 cell lysate and culture supernatant (15 mL; 70 ng/mL) were coated onto 200-mesh carbon coated/formvar copper grids for 5 min. Extra sample solution was removed with a filter paper before being stained negatively with 2% (w/v) uranyl acetate for 5 min. The grids were then viewed under a transmission electron microscope (TEM; Hitachi HT-7700, Japan).
pH and heat stability analyses
The size and homogeneity of the purified MrNV VLPs at different pH values and temperatures were determined using a dynamic light scattering (DLS) machine (DynaPro-E-50-830; Protein Solutions). For pH stability analysis, the VLPs were diluted to 50 ng/mL in buffers of different pH values: potassium chloride buffer (50 mM KCl; pH 2), sodium acetate buffer (50 mM C 2 H 3 NaO 2 ; pH 5), sodium phosphate buffer (28.9 mM Na 2 HPO 4 , 21.2 mM NaH 2 PO4; pH 7), glycine buffer (50 mM C 2 H 5 NO 2 ; pH 9), and disodium phosphate buffer (50 mM Na 2 HPO 4 ; pH 12). The samples were filtered through a membrane (0.2 mm), loaded into a sample cell and irradiated with monochromatic laser at 54 mW and wavelength of 824.8 nm. The intensity of scattered light was detected and measured to derive the translational diffusion coefficient, D T of the VLPs. The D T constant was used to determine the hydrodynamic radius, R H of the VLPs as formulated by the Stokes-Einstein equation D T 5 kT/6p˛R H , where k is the Boltzmann constant, T is the absolute temperature in Kelvin, andį s the solvent viscosity. For each sample, 15 readings were collected to obtain the average R H of the protein at 258C.
For the heat stability analysis, MrNV VLPs (50 ng/mL; pH 7.4) were subjected to in situ temperature changes and their R H values were determined by using the DLS machine as described above.
Enzyme-Linked Immunosorbent Assay
MrNV VLPs (50 mL; 25 ng and 50 ng) and skimmed milk [2% (w/v) in TBS; as a negative control] were added in triplicates into each of the 96-well plates and incubated overnight at 48C. The wells were then rinsed three times with TBST and blocked with milk diluent (100 mL; KPL) for 1.5 h. The wells were rinsed with TBST again and incubated for 1 h at room temperature upon the addition of rabbit antiMrNV capsid protein serum (1:1000 dilution in TBS). The wells were washed three times and incubated for 1 h with TBS buffer containing anti-rabbit IgG antibody (1:5000 dilution; KPL, USA). The wells were then washed three times. Next, 50 lL of p-nitrophenyl phosphate (p-npp) was added, followed by incubation for 20 min. The absorbance at wavelength 405 nm (A 405 ) was measured using the ELx800 microtiter plate reader (BioTek).
Nucleic acid analysis
Nucleic acids encapsidated by the purified MrNV VLPs (0.77 mg/mL, 350 mL) were extracted using phenolchloroform-isoamyl alcohol (25:24:1), precipitated with isopropanol and sodium acetate (0.3 M; pH 5.2) and resuspended in nuclease-free water (30 mL). 19 The extracted nucleic acids were treated with DNase I (0.1 mg/mL) or/and RNase A (0.2 mg/mL) for 1 h at 378C. The treated samples were then analyzed using 1% (w/v) agarose gel electrophoresis. The extracted nucleic acids were further analyzed using 0.4% (w/v) agarose gel electrophoresis at 50 V for 7 h to determine the size of the encapsidated DNA.
Estimation of the yield and production cost of MrNV capsid proteins in Sf9 and E. coli
The yields of MrNV capsid protein produced in Sf9 and E. coli were quantified using the Bradford assay based on 1 L culture. The cost of production for MrNV capsid protein using Sf9 and E. coli cells was estimated based on the media and chemicals needed to produce 1 mg of the proteins using the Bac-to-Bac From SDS-PAGE and Western blotting, both the infected Sf9 cell pellet and culture supernatant contained an extra protein band of approximately 48 kDa compared to those of the mock-infected cells which served as negative controls ( Figure  1 ). The molecular mass of this protein (48 kDa) corresponded well with the calculated mass (47.6 kDa) of MrNV capsid protein with an additional 25 amino acid residues (SYYHHHHHHDYDIPTTENLYFQGAM) at its N-terminal end, which contains a 6X His-tag for ease of detection. A smaller protein band of 45 kDa was observed in the cell lysate of Sf9 infected with the recombinant baculovirus when the blot was probed with a rabbit anti-MrNV capsid serum ( Figure 1C, lane 1) . However, this smaller band was not observed on the blot probed with the anti-His antibody (Figure 1B, lane 1) . This suggests that the smaller band could be an N-terminal degraded product of the MrNV capsid protein, which was also reported by Goh et al. 12 and Yong et al. 16 for the recombinant MrNV capsid proteins produced in E. coli.
Purification of MrNV VLPs
The MrNV capsid protein in Sf9 cell lysate and culture supernatant was precipitated with ammonium sulphate and purified with 10-40% sucrose density gradient ultracentrifugation. Among the 12 fractions collected, a single band of approximately 48 kDa was observed in each of the fractions 10, 11 and 12 (Figure 2) , suggesting that the MrNV capsid protein formed larger particles and migrated into the gradient.
Transmission electron microscopy of MrNV VLPs
Transmission electron microscopy revealed that the purified MrNV capsid protein from Sf9 cell lysate and culture medium formed icosahedral particles each of approximately 39 6 2 nm in diameter ( Figures 3A, B) . The shape of the VLPs produced in Sf9 cells was more uniform and about 10 nm bigger than the VLPs produced in E. coli which each had a diameter of about 30 6 3 nm and whose shapes were not uniform ( Figure 3C ).
pH and heat stability analysis DLS analysis showed that the purified MrNV VLPs from Sf9 cells contained only one population of VLPs with a hydrodynamic radius (R H ) ranging from 20.48 to 24.10 nm, from pH 2 to 12 ( Table 1 ). The mean of the R H was within the standard deviations. This implies that the MrNV VLPs produced in Sf9 cells are stable across a wide pH ranging from 2 to 12.
For the heat stability study, the R H of the MrNV VLPs measured with DLS ranged from 21.46 to 23.95 nm, from 5 to 458C (Table 2 ). The mean of the R H was within the standard deviations. Beyond 458C, the size of the VLPs could not be measured by DLS as the proteins denatured. This indicates that the VLPs are stable from 5 to 458C.
Enzyme-linked immunosorbent assay
The antigenicity of the MrNV VLPs produced in Sf9 cells was analyzed with enzyme-linked immunosorbent assay (ELISA) using the serum of a rabbit immunized with MrNV VLPs produced in E. coli. Skimmed milk was used as a negative control, whereas an equal amount of purified MrNV VLPs produced in E. coli served as a positive control. The results showed that the rabbit serum had about the same affinity (within the standard deviations) toward the VLPs produced by Sf9 cells and E. coli (Figure 4 ). This suggests that both the MrNV VLPs produced by the eukaryotic and prokaryotic cells contain similar epitopes, despite their differences in morphology.
Nucleic acid analysis
Nucleic acids extracted from the purified MrNV VLPs produced in Sf9 cells gave a distinct band which migrated at the same rate as the 23 kbp DNA of the Lambda DNA/ HindIII marker ( Figure 5A ). Upon DNase I treatment, this band was degraded, suggesting that it was a DNA band. The lower smearing nucleic acids were degraded when treated with RNase A, indicating that they were RNA. When incubated with both DNase I and RNase A, all the nucleic acids were totally cleaved, which demonstrated that the MrNV VLPs produced in Sf9 cells contained both DNA and RNA molecules.
The nucleic acid sample was further analyzed using 0.4% (w/v) agarose gel electrophoresis to determine the size of the DNA packaged inside the VLPs. Figure 5B shows that the encapsidated DNA was approximately 48 kbp.
Comparison between the Sf9 and E. coli expression systems in the production of MrNV capsid proteins A comparison between the MrNV capsid protein produced in Sf9 and E. coli is summarized in Table 3 . Approximately 8.5 and 1.5 mg of MrNV capsid protein was produced in 1 L of Sf9 and E. coli culture, respectively. The production cost for 1 mg of MrNV capsid protein in Sf9 and E. coli cells was approximately USD 19 and USD 15, respectively.
Discussion
MrNV VLPs produced in E. coli have been used in diagnosis, vaccine development, and nucleic acid delivery. However, the instability of the VLPs' monomer has been a limiting factor for its use in structural studies. To the best of our knowledge, MrNV VLPs have yet to be produced in insect cells. In this study, the gene encoding MrNV capsid protein was cloned downstream of the AcMNPV polyhedrin promoter for high-level protein expression in Sf9 cells. The recombinant MrNV capsid protein produced in Sf9 cells was approximately 48 kDa as shown by SDS-PAGE and Western blotting, which corresponded well with the calculated mass of 47.6 kDa. The recombinant MrNV capsid protein was detected inside the Sf9 cells and the culture supernatant.
Both the intracellular and extracellular MrNV capsid proteins assembled into VLPs when analyzed with sucrose density gradient ultracentrifugation. DLS and TEM analyses revealed that both the MrNV capsid proteins formed spherical VLPs of approximately 40 nm in diameter each. Interestingly, the MrNV VLPs produced in Sf9 cells appeared significantly larger compared with native MrNV, which had been reported to have a diameter of 25-30 nm.
1,11 Yong et al. 17 fused one, three and five copies of the M2e domain of influenza A virus to the MrNV capsid protein and produced the chimeric proteins in E. coli. The fusion increased the size of the capsid monomers to 48.6, 54.1, and 59.7 kDa, respectively. However, the size of the VLPs formed by the chimeric proteins did not increase. This indicates that the larger Sf9 MrNV VLPs are assembled from a greater number of monomers arranged in a different conformation when compared with native MrNV. This particle polymorphism is not unusual for icosahedral viruses. [21] [22] [23] One of the most well-studied viral capsid proteins is the hepatitis B virus (HBV) core antigen (HBcAg) which assembles into small and large icosahedral VLPs with triangulation (T) numbers of T 5 3 and T 5 4, respectively. 21 Zlotnick et al. 21 identified a region at the C-terminus of HBcAg which is responsible for the dimorphism of the VLPs, and the deletion of this The MrNV VLPs produced in Sf9 cells and E. coli were highly antigenic towards the serum from a rabbit immunized with MrNV VLPs produced in E. coli.
region (residues 141-149) dramatically reduced the T 5 3 isomorph. Apart from (HBV), Thuman-Commike et al. 22 demonstrated that in the absence of a scaffolding protein, the coat proteins of Salmonella typhimurium phage P22 assembled into the native T 5 7 and a smaller T 5 4 procapsids. Krol et al. 23 showed that the brome mosaic virus (BMV) containing the viral genomic RNA had a T 5 3 icosahedral structure, whereas the recombinant capsid protein that packaged mRNA molecules assembled into T 5 2 particles. 23 In addition, Dong et al. 24 reported that the geometry of VLPs was affected by the length of the RNA packaged within the particles.
MrNV VLPs produced in Sf9 cells were compared with those expressed in E. coli. The MrNV capsid protein produced in E. coli assembled into smaller spherical particles of about 30 nm, which was approximately 10 nm smaller than those produced in Sf9 cells. Apart from different nucleic acids being packaged, the assembly pathways of the MrNV VLPs in E. coli and Sf9 cells could be different. Salunke et al. 25 produced polymorphic VLPs from the major capsid protein (VP1) of polyomavirus in E. coli. However, when the VP1 protein was expressed in Sf9 cells, it assembled into VLPs of uniform size. 26 Chromy et al. 27 showed that chaperone proteins were needed for the in vitro assembly of polyomavirus VP1 into particles of uniform size in an energy-dependent manner. A more recent study by Bajaj and Banerjee 28 on the in vitro assembly of Flock House virus (FHV) VLPs revealed that the coat protein assembled into VLPs of various sizes in the absence of the chaperone and scaffolding proteins. This indicates that different hosts could have different systems for particle assembly, resulting in VLPs of different sizes. MrNV VLPs expressed in Sf9 cells were also found to have a more uniform morphology compared to E. coli produced MrNV VLPs. The heterogeneity of the VLP morphology produced in E. coli could be due to Nterminal degradation of the subunits as reported by Goh et al. 12 Despite the differences in size and morphology, the VLPs produced by the eukaryotic and prokaryotic cells shared high similarities in their displayed epitopes. Hence, these could be used in the production of anti-MrNV antibody for diagnosis of the virus. Theoretically, the larger VLPs should be made up of more capsid subunits, thus making them more capable of displaying foreign epitopes at higher densities which often induced stronger immune responses. 29, 30 Nucleic acid analysis showed that the MrNV VLPs produced in Sf9 cells were associated with both DNA and RNA, whereas the VLPs in E. coli contained only RNA molecules. 12 Some of the large viruses such as mimivirus and human cytomegalovirus had been shown to encapsidate viral RNA transcripts despite being DNA viruses. 31, 32 VLPs of cucumber mosaic virus were reported to be capable of encapsidating DNA and RNA in vitro when the particles were denatured and renatured in the presence of these nucleic acids. 33 To the best of our knowledge, this article is the first to report the encapsidation of both DNA and RNA by VLPs assembled within a host cell. Zhou et al. 34 and Goh et al. 13 speculated that the encapsulation of nucleic acids by MrNV VLPs produced in E. coli was due to the non-specific electrostatic interactions between the basic N-terminal end of the capsid protein and the negatively charged phosphate groups of the nucleic acids. Marshall and Schneemann 35 had demonstrated the importance of the N-terminus of FHV capsid protein produced in Drosophila melanogaster cells through the baculovirus expression system in its specific packaging of the viral RNA2. MrNV capsid protein produced in Sf9 cells may possess a similar characteristic in that it selectively packaged the VLPs associated DNA (48 kbp), contributing to larger VLPs compared to those produced in E. coli. Before the MrNV VLPs could be utilized for in vivo studies, the nucleic acids packaged within the VLPs should be characterized to avoid any undesirable effects.
Concerning production yield, 1 L suspension culture of Sf9 cells gave rise to 8.5 mg of MrNV VLPs, which was at least 5 times higher than that produced in the same volume of E. coli culture. However, to produce the same amount of MrNV VLPs, the baculovirus system cost was about 25% higher than that of the E. coli system. With respect to the duration of production, a total of 6 days was needed for the baculovirus system with the first four days being labor-free compared to a total of 3 days for the E. coli system. Thus, the baculovirus expression system could be a preferable choice over the E. coli system for a better quality of the desired protein, albeit with a longer production time.
Conclusion
Overall, the MrNV VLPs produced in Sf9 cells are distinctive from those produced in E. coli, in that their structure is more uniform and larger. The stability of the VLPs (pH ranging from 2 to 12 and temperature up to 458C) justifies their applications in structural and immunological studies, as well as in host-pathogen interaction studies. Lastly, with their capability to package both RNA and DNA of approximately 48 kbp in size, MrNV VLPs produced in Sf9 cells could be employed as a robust vessel for nucleic acid delivery. This could further contribute to the field of gene therapy.
